Sionna Therapeutics Q1 net loss widens to $26.78 million; operating loss widens to $29.6 million

Sionna Therapeutics

Sionna Therapeutics

SION

0.00
  • Sionna Therapeutics posted a net loss of USD 26.78 million, widening from USD 16.48 million a year earlier.
  • Operating loss deepened to USD 29.6 million as operating expenses climbed to USD 29.6 million from USD 19.66 million.
  • Research and development expense rose to USD 18.96 million from USD 13.67 million, driven by higher clinical programs and combination development activity.
  • General and administrative expense increased to USD 10.64 million from USD 5.99 million on higher personnel-related costs, including stock-based compensation.
  • Cash, cash equivalents, and marketable securities totaled USD 289.9 million, with runway expected to fund operations into 2028; Phase 2a PreciSION CF enrollment for SION-719 completed, with topline data for that trial and a Phase 1 dual-combination study expected in summer 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-033876), on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.